Strides Pharma gets DCGI nod under EUA to commercialize Molnupiravir

28 Dec 2021 Evaluate

Strides Pharma Science has received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) to launch Molnupiravir 200mg in India.  Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS?CoV?2 and the clinical studies have shown this drug to be active against the most common Covid?19 variants.  

Under the brand name ‘Stripiravir’, Strides has developed Molnupiravir and is commercializing the product with a group integrated supply chain for Active Pharmaceutical Ingredients and solid oral dosage from its large?scale WHO Pre?Qualified (PQ) manufacturing capacities.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.

Strides Pharma Scien Share Price

878.65 -7.00 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×